Elevated expression of MeCP2 in cardiac and skeletal tissues is detrimental for normal development

Human Molecular Genetics

Volumn 19, Issue 11, 2010, Pages 2177-2190

  Alvarez Saavedra, Matías ^a,d   Carrasco, Loreto ^a   Sura Trueba, Sylvia ^b   Aiello, Vera Demarchi ^b   Walz, Katherina ^a,c   Neto, José Xavier ^b   Young, Juan I ^a,c  

^a CENTRO DE ESTUDIOS CIENTÍFICOS CECS   (Chile)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

METHYL CPG BINDING PROTEIN 2; ALCIAN BLUE; ALIZARIN; ANTHRAQUINONE DERIVATIVE; BROXURIDINE; MECP2 PROTEIN, MOUSE; PRIMER DNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MALFORMATION; CONTROLLED STUDY; EMBRYO; EMBRYO DEATH; EMBRYO DEVELOPMENT; FEMALE; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HEART HYPERTROPHY; HEART VENTRICLE SEPTUM; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; TRANSCRIPTION REGULATION; ANIMAL; BONE; BONE DEVELOPMENT; CROSS BREEDING; EMBRYOLOGY; FLUORESCENCE MICROSCOPY; GENETICS; HEART; HEART MUSCLE; IN SITU HYBRIDIZATION; METABOLISM; NICK END LABELING; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSGENE; TRANSGENIC MOUSE;

ALCIAN BLUE; ANIMALS; ANTHRAQUINONES; BONE AND BONES; BROMODEOXYURIDINE; CROSSES, GENETIC; DNA PRIMERS; GENE EXPRESSION REGULATION, DEVELOPMENTAL; HEART; IN SITU HYBRIDIZATION; IN SITU NICK-END LABELING; METHYL-CPG-BINDING PROTEIN 2; MICE; MICE, TRANSGENIC; MICROSCOPY, FLUORESCENCE; MYOCARDIUM; OSTEOGENESIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSGENES;

EID: 77953533210     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddq096     Document Type: Article

References (99)

1. Bird, A. (2002) DNA methylation patterns and epigenetic memory. Genes Dev., 16, 6-21.
2. Goll, M.G. and Bestor, T.H. (2005) Eukaryotic cytosine methyltransferases. Annu. Rev. Biochem., 74, 481-514.
3. Jackson-Grusby, L., Beard, C., Possemato, R., Tudor, M., Fambrough, D., Csankovszki, G., Dausman, J., Lee, P., Wilson, C., Lander, E. and Jaenisch, R. (2001) Loss of genomic methylation causes p53-dependent apoptosis and epigenetic deregulation. Nat. Genet., 27, 31-39.
4. Li, E., Bestor, T.H. and Jaenisch, R. (1992) Targeted mutation of the DNA methyltransferase gene results in embryonic lethality. Cell, 69, 915-926.
5. Okano, M., Bell, D.W., Haber, D.A. and Li, E. (1999) DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell, 99, 247-257.
6. Hore, T.A., Rapkins, R.W. and Graves, J.A. (2007) Construction and evolution of imprinted loci in mammals. Trends Genet., 23, 440-448.
7. Miranda, T.B. and Jones, P.A. (2007) DNA methylation: the nuts and bolts of repression. J. Cell Physiol., 213, 384-390.
8. Yen, Z.C., Meyer, I.M., Karalic, S. and Brown, C.J. (2007) A cross-species comparison of X-chromosome inactivation in Eutheria. Genomics, 90, 453-463.
9. Howard, G., Eiges, R., Gaudet, F., Jaenisch, R. and Eden, A. (2008) Activation and transposition of endogenous retroviral elements in hypomethylation induced tumors in mice. Oncogene, 27, 404-408.
10. Yoder, J.A., Walsh, C.P. and Bestor, T.H. (1997) Cytosine methylation and the ecology of intragenomic parasites. Trends Genet., 13, 335-340.
11. Reik, W. (2007) Stability and flexibility of epigenetic gene regulation in mammalian development. Nature, 447, 425-432.
12. Yang, J., Yang, S., Beaujean, N., Niu, Y., He, X., Xie, Y., Tang, X., Wang, L., Zhou, Q. and Ji, W. (2007) Epigenetic marks in cloned rhesus monkey embryos: comparison with counterparts produced in vitro. Biol. Reprod., 76, 36-42.
13. Gronbaek, K., Hother, C. and Jones, P.A. (2007) Epigenetic changes in cancer. APMIS, 115, 1039-1059.
14. Walsh, C.P. and Xu, G.L. (2006) Cytosine methylation and DNA repair. Curr. Top. Microbiol. Immunol., 301, 283-315.
15. Schaefer, C.B., Ooi, S.K., Bestor, T.H. and Bourc'his, D. (2007) Epigenetic decisions in mammalian germ cells. Science, 316, 398-399.
16. Unterberger, A., Andrews, S.D., Weaver, I.C. and Szyf, M. (2006) DNA methyltransferase 1 knockdown activates a replication stress checkpoint. Mol. Cell Biol., 26, 7575-7586.
17. Hendrich, B. and Bird, A. (1998) Identification and characterization of a family of mammalian methyl-CpG binding proteins. Mol. Cell Biol., 18, 6538-6547.
18. Nan, X., Meehan, R.R. and Bird, A. (1993) Dissection of the methyl-CpG binding domain from the chromosomal protein MeCP2. Nucleic Acids Res., 21, 4886-4892.
19. Jones, P.L., Veenstra, G.J., Wade, P.A., Vermaak, D., Kass, S.U., Landsberger, N., Strouboulis, J. and Wolffe, A.P. (1998) Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat. Genet., 19, 187-191.
20. Nan, X., Ng, H.H., Johnson, C.A., Laherty, C.D., Turner, B.M., Eisenman, R.N. and Bird, A. (1998) Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature, 393, 386-389.
21. Suzuki, M., Yamada, T., Kihara-Negishi, F., Sakurai, T. and Oikawa, T. (2003) Direct association between PU.1 and MeCP2 that recruits mSin3A-HDAC complex for PU.1-mediated transcriptional repression. Oncogene, 22, 8688-8698.
22. Stancheva, I., Collins, A.L., Van den Veyver, I.B., Zoghbi, H. and Meehan, R.R. (2003) A mutant form of MeCP2 protein associated with human Rett syndrome cannot be displaced from methylated DNA by notch in Xenopus embryos. Mol. Cell, 12, 425-435.
23. Fuks, F., Hurd, P.J., Wolf, D., Nan, X., Bird, A.P. and Kouzarides, T. (2003) The methyl-CpG-binding protein MeCP2 links DNA methylation to histone methylation. J. Biol. Chem., 278, 4035-4040.
24. Kimura, H. and Shiota, K. (2003) Methyl-CpG-binding protein, MeCP2, is a target molecule for maintenance DNA methyltransferase, Dnmt1. J. Biol. Chem., 278, 4806-4812.
25. Kokura, K., Kaul, S.C., Wadhwa, R., Nomura, T., Khan, M.M., Shinagawa, T., Yasukawa, T., Colmenares, C. and Ishii, S. (2001) The Ski protein family is required for MeCP2-mediated transcriptional repression. J. Biol. Chem., 276, 34115-34121.
26. Yasui, D.H., Peddada, S., Bieda, M.C., Vallero, R.O., Hogart, A., Nagarajan, R.P., Thatcher, K.N., Farnham, P.J. and Lasalle, J.M. (2007) Integrated epigenomic analyses of neuronal MeCP2 reveal a role for long-range interaction with active genes. Proc. Natl Acad. Sci. USA, 104, 19416-19421.
27. Chahrour, M., Jung, S.Y., Shaw, C., Zhou, X., Wong, S.T., Qin, J. and Zoghbi, H.Y. (2008) MeCP2, a key contributor to neurological disease, activates and represses transcription. Science, 320, 1224-1229.
28. Young, J.I., Hong, E.P., Castle, J.C., Crespo-Barreto, J., Bowman, A.B., Rose, M.F., Kang, D., Richman, R., Johnson, J.M., Berget, S. and Zoghbi, H.Y. (2005) Regulation of RNA splicing by the methylation-dependent transcriptional repressor methyl-CpG binding protein 2. Proc. Natl Acad. Sci. USA, 102, 17551-17558.
29. Buschdorf, J.P. and Stratling, W.H. (2004) A WW domain binding region in methyl-CpG-binding protein MeCP2: impact on Rett syndrome. J. Mol. Med., 82, 135-143.
30. Chen, W.G., Chang, Q., Lin, Y., Meissner, A., West, A.E., Griffith, E.C., Jaenisch, R. and Greenberg, M.E. (2003) Derepression of BDNF transcription involves calcium-dependent phosphorylation of MeCP2. Science, 302, 885-889.
31. Martinowich, K., Hattori, D., Wu, H., Fouse, S., He, F., Hu, Y., Fan, G. and Sun, Y.E. (2003) DNA methylation-related chromatin remodeling in activity-dependent BDNF gene regulation. Science, 302, 890-893.
32. Zhou, Z., Hong, E.J., Cohen, S., Zhao, W.N., Ho, H.Y., Schmidt, L., Chen, W.G., Lin, Y., Savner, E., Griffith, E.C. et al. (2006) Brain-specific phosphorylation of MeCP2 regulates activity-dependent Bdnf transcription, dendritic growth, and spine maturation. Neuron, 52, 255-269.
33. Miyake, K. and Nagai, K. (2007) Phosphorylation of methyl-CpG binding protein 2 (MeCP2) regulates the intracellular localization during neuronal cell differentiation. Neurochem. Int., 50, 264-270.
34. Adachi, M., Keefer, E.W. and Jones, F.S. (2005) A segment of the Mecp2 promoter is sufficient to drive expression in neurons. Hum. Mol. Genet., 14, 3709-3722.
35. Reichwald, K., Thiesen, J., Wiehe, T., Weitzel, J., Poustka, W.A., Rosenthal, A., Platzer, M., Stratling, W.H. and Kioschis, P. (2000) Comparative sequence analysis of the MECP2-locus in human and mouse reveals new transcribed regions. Mamm. Genome, 11, 182-190.
36. Shahbazian, M.D., Antalffy, B., Armstrong, D.L. and Zoghbi, H.Y. (2002) Insight into Rett syndrome: MeCP2 levels display tissueand cell-specific differences and correlate with neuronal maturation. Hum. Mol. Genet., 11, 115-124.
37. D'Esposito, M., Quaderi, N.A., Ciccodicola, A., Bruni, P., Esposito, T., D'Urso, M. and Brown, S.D. (1996) Isolation, physical mapping, and northern analysis of the X-linked human gene encoding methyl CpG-binding protein, MECP2. Mamm. Genome, 7, 533-535.
38. Coy, J.F., Sedlacek, Z., Bachner, D., Delius, H. and Poustka, A. (1999) A complex pattern of evolutionary conservation and alternative polyadenylation within the long 3′-untranslated region of the methyl-CpG-binding protein 2 gene (MeCP2) suggests a regulatory role in gene expression. Hum. Mol. Genet., 8, 1253-1262.
39. Mnatzakanian, G.N., Lohi, H., Munteanu, I., Alfred, S.E., Yamada, T., MacLeod, P.J., Jones, J.R., Scherer, S.W., Schanen, N.C., Friez, M.J. et al. (2004) A previously unidentified MECP2 open reading frame defines a new protein isoform relevant to Rett syndrome. Nat. Genet., 36, 339-341.
40. Kriaucionis, S. and Bird, A. (2004) The major form of MeCP2 has a novel N-terminus generated by alternative splicing. Nucleic Acids Res., 32, 1818-1823.
41. Dragich, J.M., Kim, Y.H., Arnold, A.P. and Schanen, N.C. (2007) Differential distribution of the MeCP2 splice variants in the postnatal mouse brain. J. Comp. Neurol., 501, 526-542.
42. Parmeggiani, A., Tedde, M.R., Arbizzani, A., Posar, A., Scaduto, M.C., Santucci, M. and Sangiorgi, S. (2009) Methyl-CpG-binding protein 2 (MECP2) gene mutations in an Italian sample of patients with pervasive developmental disorder and mental retardation. J. Child Neurol., 24, 772-774.
43. Villard, L. (2007) MECP2 mutations in males. J. Med. Genet., 44, 417-423.
44. Adegbola, A.A., Gonzales, M.L., Chess, A., Lasalle, J.M. and Cox, G.F. (2009) A novel hypomorphic MECP2 point mutation is associated with a neuropsychiatric phenotype. Hum. Genet., 124, 615-623.
45. del Gaudio, D., Fang, P., Scaglia, F., Ward, P.A., Craigen, W.J., Glaze, D.G., Neul, J.L., Patel, A., Lee, J.A., Irons, M. et al. (2006) Increased MECP2 gene copy number as the result of genomic duplication in neurodevelopmentally delayed males. Genet. Med., 8, 784-792.
46. Echenne, B., Roubertie, A., Lugtenberg, D., Kleefstra, T., Hamel, B.C., Van Bokhoven, H., Lacombe, D., Philippe, C., Jonveaux, P. and de Brouwer, A.P. (2009) Neurologic aspects of MECP2 gene duplication in male patients. Pediatr. Neurol., 41, 187-191.
47. Kirk, E.P., Malaty-Brevaud, V., Martini, N., Lacoste, C., Levy, N., Maclean, K., Davies, L., Philip, N. and Badens, C. (2009) The clinical variability of the MECP2 duplication syndrome: description of two families with duplications excluding L1CAM and FLNA. Clin. Genet., 75, 301-303.
48. Lugtenberg, D., Kleefstra, T., Oudakker, A.R., Nillesen, W.M., Yntema, H.G., Tzschach, A., Raynaud, M., Rating, D., Journel, H., Chelly, J. et al. (2009) Structural variation in Xq28: MECP2 duplications in 1% of patients with unexplained XLMR and in 2% of male patients with severe encephalopathy. Eur. J. Hum. Genet., 17, 444-453.
49. Van Esch, H., Bauters, M., Ignatius, J., Jansen, M., Raynaud, M., Hollanders, K., Lugtenberg, D., Bienvenu, T., Jensen, L.R., Gecz, J. et al. (2005) Duplication of the MECP2 region is a frequent cause of severe mental retardation and progressive neurological symptoms in males. Am. J. Hum. Genet., 77, 442-453.
50. Sanlaville, D., Schluth-Bolard, C. and Turleau, C. (2009) Distal Xq duplication and functional Xq disomy. Orphanet. J. Rare. Dis., 4, 4.
51. Carvalho, C.M., Zhang, F., Liu, P., Patel, A., Sahoo, T., Bacino, C.A., Shaw, C., Peacock, S., Pursley, A., Tavyev, Y.J. et al. (2009) Complex rearrangements in patients with duplications of MECP2 can occur by fork stalling and template switching. Hum. Mol. Genet., 18, 2188-2203.
52. Collins, A.L., Levenson, J.M., Vilaythong, A.P., Richman, R., Armstrong, D.L., Noebels, J.L., David, S.J. and Zoghbi, H.Y. (2004) Mild overexpression of MeCP2 causes a progressive neurological disorder in mice. Hum. Mol. Genet., 13, 2679-2689.
53. Smrt, R.D., Eaves-Egenes, J., Barkho, B.Z., Santistevan, N.J., Zhao, C., Aimone, J.B., Gage, F.H. and Zhao, X. (2007) Mecp2 deficiency leads to delayed maturation and altered gene expression in hippocampal neurons. Neurobiol. Dis., 27, 77-89.
54. Matarazzo, V., Cohen, D., Palmer, A.M., Simpson, P.J., Khokhar, B., Pan, S.J. and Ronnett, G.V. (2004) The transcriptional repressor Mecp2 regulates terminal neuronal differentiation. Mol. Cell Neurosci., 27, 44-58.
55. O'Connor, R.D., Zayzafoon, M., Farach-Carson, M.C. and Schanen, N.C. (2009) Mecp2 deficiency decreases bone formation and reduces bone volume in a rodent model of Rett syndrome. Bone, 45, 346-356.
56. Friez, M.J., Jones, J.R., Clarkson, K., Lubs, H., Abuelo, D., Bier, J.A., Pai, S., Simensen, R., Williams, C., Giampietro, P.F. et al. (2006) Recurrent infections, hypotonia, and mental retardation caused by duplication of MECP2 and adjacent region in Xq28. Pediatrics, 118, e1687-e1695.
57. Smyk, M., Obersztyn, E., Nowakowska, B., Nawara, M., Cheung, S.W., Mazurczak, T., Stankiewicz, P. and Bocian, E. (2008) Different-sized duplications of Xq28, including MECP2, in three males with mental retardation, absent or delayed speech, and recurrent infections. Am. J. Med. Genet. B Neuropsychiatr. Genet., 147B, 799-806.
58. Meins, M., Lehmann, J., Gerresheim, F., Herchenbach, J., Hagedorn, M., Hameister, K. and Epplen, J.T. (2005) Submicroscopic duplication in Xq28 causes increased expression of the MECP2 gene in a boy with severe mental retardation and features of Rett syndrome. J. Med. Genet., 42, e12.
59. Alvarez-Saavedra, M., Saez, M.A., Kang, D., Zoghbi, H.Y. and Young, J.I. (2007) Cell-specific expression of wild-type MeCP2 in mouse models of Rett syndrome yields insight about pathogenesis. Hum. Mol. Genet., 16, 2315-2325.
60. Chen, J., Kelz, M.B., Zeng, G., Sakai, N., Steffen, C., Shockett, P.E., Picciotto, M.R., Duman, R.S. and Nestler, E.J. (1998) Transgenic animals with inducible, targeted gene expression in brain. Mol. Pharmacol., 54, 495-503.
61. Hadjantonakis, A.K., Macmaster, S. and Nagy, A. (2002) Embryonic stem cells and mice expressing different GFP variants for multiple non-invasive reporter usage within a single animal. BMC Biotechnol., 2, 11.
62. Schaefer, B.C., Schaefer, M.L., Kappler, J.W., Marrack, P. and Kedl, R.M. (2001) Observation of antigen-dependent CD8+ T-cell/dendritic cell interactions in vivo. Cell Immunol., 214, 110-122.
63. Hadjantonakis, A.K., Gertsenstein, M., Ikawa, M., Okabe, M. and Nagy, A. (1998) Generating green fluorescent mice by germline transmission of green fluorescent ES cells. Mech. Dev., 76, 79-90.
64. Novak, A., Guo, C., Yang, W., Nagy, A. and Lobe, C.G. (2000) Z/EG, a double reporter mouse line that expresses enhanced green fluorescent protein upon Cre-mediated excision. Genesis, 28, 147-155.
65. Xian, M., Honbo, N., Zhang, J., Liew, C.C., Karliner, J.S. and Lau, Y.F. (1999) The green fluorescent protein is an efficient biological marker for cardiac myocytes. J. Mol. Cell Cardiol., 31, 2155-2165.
66. Huang, W.Y., Aramburu, J., Douglas, P.S. and Izumo, S. (2000) Transgenic expression of green fluorescence protein can cause dilated cardiomyopathy. Nat. Med., 6, 482-483.
67. Okabe, M., Ikawa, M., Kominami, K., Nakanishi, T. and Nishimune, Y. (1997) `Green mice' as a source of ubiquitous green cells. FEBS Lett., 407, 313-319.
68. Devgan, V., Rao, M.R. and Seshagiri, P.B. (2004) Impact of embryonic expression of enhanced green fluorescent protein on early mouse development. Biochem. Biophys. Res. Commun., 313, 1030-1036.
69. Forss-Petter, S., Danielson, P.E., Catsicas, S., Battenberg, E., Price, J., Nerenberg, M. and Sutcliffe, J.G. (1990) Transgenic mice expressing beta-galactosidase in mature neurons under neuron-specific enolase promoter control. Neuron, 5, 187-197.
70. Sabatakos, G., Sims, N.A., Chen, J., Aoki, K., Kelz, M.B., Amling, M., Bouali, Y., Mukhopadhyay, K., Ford, K., Nestler, E.J. and Baron, R. (2000) Overexpression of DeltaFosB transcription factor(s) increases bone formation and inhibits adipogenesis. Nat. Med., 6, 985-990.
71. Castillo, M.B., Celio, M.R., Andressen, C., Gotzos, V., Rulicke, T., Berger, M.C., Weber, J. and Berchtold, M.W. (1995) Production and analysis of transgenic mice with ectopic expression of parvalbumin. Arch. Biochem. Biophys., 317, 292-298.
72. Seidman, J.G. and Seidman, C. (2001) The genetic basis for cardiomyopathy: from mutation identification to mechanistic paradigms. Cell, 104, 557-567.
73. Pelka, G.J., Watson, C.M., Christodoulou, J. and Tam, P.P. (2005) Distinct expression profiles of Mecp2 transcripts with different lengths of 3′-UTR in the brain and visceral organs during mouse development. Genomics, 85, 441-452.
74. Draus, J.M. Jr, Hauck, M.A., Goetsch, M., Austin, E.H. III, Tomita-Mitchell, A. and Mitchell, M.E. (2009) Investigation of somatic NKX2-5 mutations in congenital heart disease. J. Med. Genet., 46, 115-122.
75. Kasahara, H., Wakimoto, H., Liu, M., Maguire, C.T., Converso, K.L., Shioi, T., Huang, W.Y., Manning, W.J., Paul, D., Lawitts, J. et al. (2001) Progressive atrioventricular conduction defects and heart failure in mice expressing a mutant Csx/Nkx2.5 homeoprotein. J. Clin. Invest., 108, 189-201.
76. Brown, D.D., Martz, S.N., Binder, O., Goetz, S.C., Price, B.M., Smith, J.C. and Conlon, F.L. (2005) Tbx5 and Tbx20 act synergistically to control vertebrate heart morphogenesis. Development, 132, 553-563.
77. Basson, C.T., Bachinsky, D.R., Lin, R.C., Levi, T., Elkins, J.A., Soults, J., Grayzel, D., Kroumpouzou, E., Traill, T.A., Leblanc-Straceski, J. et al. (1997) Mutations in human TBX5 [corrected] cause limb and cardiac malformation in Holt-Oram syndrome. Nat. Genet., 15, 30-35.
78. Bruneau, B.G., Nemer, G., Schmitt, J.P., Charron, F., Robitaille, L., Caron, S., Conner, D.A., Gessler, M., Nemer, M., Seidman, C.E. and Seidman, J.G. (2001) A murine model of Holt-Oram syndrome defines roles of the T-box transcription factor Tbx5 in cardiogenesis and disease. Cell, 106, 709-721.
79. Carvalho, C.M.B., Ramocki, M.B., Seaver, L., White, E., Friehling, L., Liu, P., Cheung, H., Zoghbi, H. and Lupski, J.R. (2009) Triplication of the MECP2 gene causing a severe neurodevelopmental phenotype can be induced by the presence of low copy repeats (LCRs). (Abstract #1407) Presented at the 59th Annual Meeting of The American Society of Human Genetics, 2009.
80. Tropea, D., Giacometti, E., Wilson, N.R., Beard, C., McCurry, C., Fu, D.D., Flannery, R., Jaenisch, R. and Sur, M. (2009) Partial reversal of Rett Syndrome-like symptoms in MeCP2 mutant mice. Proc. Natl Acad. Sci. USA, 106, 2029-2034.
81. Bissonnette, J.M., Knopp, S.J., Maylie, J. and Thong, T. (2007) Autonomic cardiovascular control in methyl-CpG-binding protein 2 (Mecp2) deficient mice. Auton. Neurosci., 136, 82-89.
82. Sekul, E.A., Moak, J.P., Schultz, R.J., Glaze, D.G., Dunn, J.K. and Percy, A.K. (1994) Electrocardiographic findings in Rett syndrome: an explanation for sudden death? J. Pediatr., 125, 80-82.
83. Ellaway, C.J., Sholler, G., Leonard, H. and Christodoulou, J. (1999) Prolonged QT interval in Rett syndrome. Arch. Dis. Child, 80, 470-472.
84. Fuster-Siebert, M. and Castro-Gago, M. (1995) Electrocardiographic findings in Rett syndrome. J. Pediatr., 126, 506.
85. Guideri, F., Acampa, M., Hayek, G., Zappella, M. and Di, P.T. (1999) Reduced heart rate variability in patients affected with Rett syndrome. A possible explanation for sudden death. Neuropediatrics, 30, 146-148.
86. Acampa, M. and Guideri, F. (2006) Cardiac disease and Rett syndrome. Arch. Dis. Child, 91, 440-443.
87. Glaze, D.G. (2005) Neurophysiology of Rett syndrome. J. Child Neurol., 20, 740-746.
88. Guideri, F., Acampa, M., DiPerri, T., Zappella, M. and Hayek, Y. (2001) Progressive cardiac dysautonomia observed in patients affected by classic Rett syndrome and not in the preserved speech variant. J. Child Neurol., 16, 370-373.
89. Budden, S.S. and Gunness, M.E. (2003) Possible mechanisms of osteopenia in Rett syndrome: bone histomorphometric studies. J. Child Neurol., 18, 698-702.
90. Kitazawa, R. and Kitazawa, S. (2007) Methylation status of a single CpG locus 3 bases upstream of TATA-box of receptor activator of nuclear factor-kappaB ligand (RANKL) gene promoter modulates cell-and tissue-specific RANKL expression and osteoclastogenesis. Mol. Endocrinol., 21, 148-158.
91. Komori, T., Yagi, H., Nomura, S., Yamaguchi, A., Sasaki, K., Deguchi, K., Shimizu, Y., Bronson, R.T., Gao, Y.H., Inada, M. et al. (1997) Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell, 89, 755-764.
92. Mundlos, S., Otto, F., Mundlos, C., Mulliken, J.B., Aylsworth, A.S., Albright, S., Lindhout, D., Cole, W.G., Henn, W., Knoll, J.H. et al. (1997) Mutations involving the transcription factor CBFA1 cause cleidocranial dysplasia. Cell, 89, 773-779.
93. Choi, J.Y., Pratap, J., Javed, A., Zaidi, S.K., Xing, L., Balint, E., Dalamangas, S., Boyce, B., van Wijnen, A.J., Lian, J.B. et al. (2001) Subnuclear targeting of Runx/Cbfa/AML factors is essential for tissue-specific differentiation during embryonic development. Proc. Natl Acad. Sci. USA, 98, 8650-8655.
94. Otto, F., Thornell, A.P., Crompton, T., Denzel, A., Gilmour, K.C., Rosewell, I.R., Stamp, G.W., Beddington, R.S., Mundlos, S., Olsen, B.R. et al. (1997) Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell, 89, 765-771.
95. Lee, B., Thirunavukkarasu, K., Zhou, L., Pastore, L., Baldini, A., Hecht, J., Geoffroy, V., Ducy, P. and Karsenty, G. (1997) Missense mutations abolishing DNA binding of the osteoblast-specific transcription factor OSF2/CBFA1 in cleidocranial dysplasia. Nat. Genet., 16, 307-310.
96. Otto, F., Kanegane, H. and Mundlos, S. (2002) Mutations in the RUNX2 gene in patients with cleidocranial dysplasia. Hum. Mutat., 19, 209-216.
97. Yoshida, T., Kanegane, H., Osato, M., Yanagida, M., Miyawaki, T., Ito, Y. and Shigesada, K. (2003) Functional analysis of RUNX2 mutations in cleidocranial dysplasia: novel insights into genotype-phenotype correlations. Blood Cells Mol. Dis., 30, 184-193.
98. Wilkinson, D. (1992) Whole Mount in situ Hybridization: A Practical Approach. IRL Press, Oxford, UK.
99. Bruneau, B.G., Logan, M., Davis, N., Levi, T., Tabin, C.J., Seidman, J.G. and Seidman, C.E. (1999) Chamber-specific cardiac expression of Tbx5 and heart defects in Holt-Oram syndrome. Dev. Biol., 211, 100-108.